The convoluted process of diagnosing pulmonary mycosis caused by *Exophiala dermatitidis*: a case report

Zhengtu Li\(^1\)†, Jianli Tang\(^1\)†, Jinping Zhu\(^2\), Mingzhou Xie\(^3\), Shaoqing Huang\(^1\), Shaoqiang Li\(^1\), Yangqing Zhan\(^1\), Weiqi Zeng\(^3\), Teng Xu\(^2\) and Feng Ye\(^1\)*

**Abstract**

**Background:** Etiological diagnosis is a key step in the treatment of patients with rare pulmonary mycosis, and the lack of understanding of this disease and lack of specific markers for the detection of rare species, such as *Exophiala dermatitidis*, add to the difficulty in diagnosing the condition. Therefore, improving the diagnostic strategies for this disease is very important.

**Case presentation:** A 52-year-old man presented with cough, sputum production and hemoptysis; chest computed tomography (CT) revealed multiple bilateral lesions. The pathogen was unable to be identified after three biopsies. Subsequently, we performed combined tissue metagenomic next-generation sequencing (mNGS). The results of mNGS and a good therapeutic response helped to identify the causative pathogen as *Exophiala dermatitidis*. Finally, the patient was diagnosed with *Exophiala dermatitidis* pneumonia.

**Conclusions:** Combining molecular techniques, such as mNGS, with clinical microbiological tests will improve the rate of positivity in the diagnosis of rare fungal infections, and the importance of follow-up should be emphasized.

**Keywords:** *Exophiala dermatitidis*, Tissue mNGS, Antifungal therapy, Follow-up, Case report

**Background**

*Exophiala dermatitidis*, a rare fungal species, can cause pulmonary mycosis. Due to the lack of understanding of this condition as well as the lack of specific markers, diagnosing pulmonary mycosis caused by *Exophiala dermatitidis* is challenging. The key requirement for the management of the disease and the development of treatment strategies for infected patients is the identification of pathogens from clinical samples [1]. However, traditional methods for the detection of pathogenic microorganisms, including morphological detection, culture, microscopy, antigen–antibody detection, and nucleic acid detection, have inevitable shortcomings. For example, microbial culture is time consuming and has a low positivity rate [2], and molecular diagnostic methods, such as PCR, can detect one or more target-specific pathogens but miss pathogens that are not targeted by the primer set, making this approach unsuitable for the detection of pathogens in difficult-to-diagnose infectious diseases. A new technology, metagenomic next-generation sequencing (mNGS), is being widely used in clinical practice to detect bacteria, fungi, viruses, atypical pathogens, parasites, and new pathogens in respiratory specimens, overcoming the limitations of traditional microbial...
specific underlying disease. Routine laboratory tests revealed a CD4+/CD8+ ratio of 1.03 (1.4–2.0), absolute T lymphocyte count of 705/µL (955–2860), and absolute T helper lymphocyte count of 344/µL (550–1440). A white blood cell count of 9560/µL, with 7800/µL neutrophils, was also observed. The procalcitonin level was <0.05 ng/mL. A blood T-SPOT tuberculosis (TB) test (interferon gamma release assay, IGRA) was positive (antigen A: ESAT-6: 21 spots), but sputum and bronchoalveolar lavage fluid (BALF) cultures, sputum TB DNA detection; BALF X-Pert galactomannan (GM), (1→3)-β-D-glucan (BG) assays; and the Cryptococcus antigen test (GM test) was positive, but the results of other pathogen tests (including sputum smear and culture) were negative. The diagnosis was a fungal infection, and he was prescribed oral voriconazole (200 mg, bid). The symptoms of cough and sputum production improved. However, hemoptysis developed on the sixth day of treatment, and the patient visited our hospital (the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China).

He had a smoking index of 200 (20 cigarettes/day for 20 years), body mass index (BMI) of 19.47 kg/m² and no specific underlying disease. At admission, no significant abnormalities were found on physical examination. Chest CT revealed multiple nodules and mass lesions throughout both lungs, mainly under the pleura, particularly in the right upper and lower lung (Fig. 1B, April 4, 2019). Routine laboratory tests revealed a CD4+/CD8+ ratio of 1.03 (1.4–2.0), absolute T lymphocyte count of 705/µL (955–2860), and absolute T helper lymphocyte count of 344/µL (550–1440). A white blood cell count of 9560/µL, with 7800/µL neutrophils, was also observed. The procalcitonin level was <0.05 ng/mL. A blood T-SPOT tuberculosis (TB) test (interferon gamma release assay, IGRA) was positive (antigen A: ESAT-6: 21 spots), but sputum and bronchoalveolar lavage fluid (BALF) cultures, sputum TB DNA detection; BALF X-Pert galactomannan (GM), (1→3)-β-D-glucan (BG) assays; and the Cryptococcus antigen test was negative. Levels of lung tumor indicators were normal. Levels of antinuclear antibodies and vasculitis indicators were normal. Two successive biopsies were performed via bronchoscopy (posterior RB2) and percutaneous lung puncture guided by B-mode ultrasound (posterior-basal RB10). Unfortunately, the histopathologic results indicated inflammation with an unknown cause, and the antacid fluorescence and culture results were negative.

After stopping oral voriconazole because of a lack of evidence of fungal infection, the patient was discharged from the hospital, and his treatment was adjusted to oral moxifloxacin hydrochloride (0.4 g qd). Half a month later, he returned to our hospital due to hemoptysis recurrence. Based on this condition and other clinical features, we considered an infectious disease. From a paraffin-embedded tissue sample (from posterior-basal RB10), clinical mNGS identified 118 unique sequence reads for Exophiala dermatitidis (Fig. 2B) in addition to normal respiratory/skin flora[4, 5] (Fig. 2C). The close identity with two sequences from Exophiala spp. downloaded from the NCBI is shown in Additional file 1: Fig. S1.

Without other etiological evidence, we diagnosed the patient with Exophiala dermatitidis pneumonia. Because of the lack of drug susceptibility data, we had to review the literature and refer to our experience with medications. After diagnosis, we supposed that the previously administered course of voriconazole treatment was insufficient. Therefore, the patient was treated with intravenous voriconazole (the first dose was 300 mg (6 mg/kg) bid, followed by 200 mg (4 mg/kg) bid) for maintenance. The patient was switched to oral voriconazole (200 mg bid) after discharge.

During a telephone follow-up, the patient told us that his clinical symptoms had been significantly alleviated. Two months later, he was hospitalized for assessment and complained of occasional hemoptysis. Laboratory tests indicated liver dysfunction, with an alanine aminotransferase (ALT) level of 124.4 U/L and a γ-glutamyl transpeptidase level of 107.7 U/L. The trough serum concentration of voriconazole was 0.33 μg/mL (0.5–5.0). Re-examination with chest CT revealed the progression of some lesions in the posterior right upper lung and right lower lung, while some of the other lesions had been absorbed (Fig. 1C, June 14, 2019). Based on the adverse effects and poor efficacy of the drug, on June 22, 2019, we decided to stop voriconazole and adjust the treatment plan of amphotericin B (started at a dose of 5 mg/d and gradually increased until a maintenance dose of 30 mg/d was reached). Additionally, we strengthened hydration treatment for kidney protection and orally administered potassium to prevent hypokalemia. The patient had no further hemoptysis events and tolerated treatment well. When the cumulative dose of amphotericin B reached 555 mg, he returned to our hospital for imaging re-examination, and no increase in the size of the lesion was observed.
To clarify whether the lesion in the right upper lung was homogenous with the posterior-basal RB10 sample, we sampled posterior RB2 lung tissue again via bronchoscopy. Pathological examination revealed granulomatous inflammation and antacid 2 and antacid fluorescence positivity (Fig. 2A). The paraffin-embedded tissue was subjected to clinical mNGS again, and the results showed that only specific Exophiala dermatitidis sequence reads were detected, and the number of reads was reduced by only 1 (Fig. 2D). Based on the clinical characteristics, including lack of fever and night sweats; potential positivity on the blood T-SPOT test due to...
possible prior TB infection, which likely induced memory cell generation in the body; repeatedly negative BALF TB-DNA, X-Pert, sputum and BALF TB culture results; and the poor response to antifungal therapy in the early stage, we did not consider TB infection. We continued the current treatment regimen in a local hospital and performed follow-up. After 3 months, the cumulative dose of amphotericin reached 2935 mg, and chest CT showed that lung lesions had been obviously absorbed, leaving only a thin-walled cavity (Fig. 1D, October 12, 2019). The patient had no symptom of cough or hemoptysis. We discontinued amphotericin B treatment and
administered posaconazole (200 mg, qid) orally to avoid prolonged intravenous drug use. After half a month, there was no change in the lesion. We judged that the patient had achieved clinical cure and terminated treatment. Two months later, a follow-up chest CT scan showed no change (Fig. 1E, December 7, 2019). Finally, we confirmed that the pathogen causing the patient’s infection was Exophiala dermatitidis. The patient’s clinical timeline and schedule of medications are shown in Fig. 1-A.

**Discussion and conclusions**

*Exophiala dermatitidis* is a saprophytic fungus that is usually present in decaying plants and soil. It can also be found in high-temperature and high-humidity areas, such as dishwashers, bathrooms or sauna facilities, in anthropogenic environments. It has also been isolated from railroad sleepers in subtropical areas. It is a rare conditional pathogen that often causes phaeohyphomycosis [6]. It can colonize lung transplantation wounds and cause rapidly progressing invasive dermatitis [7], which has been reported in cystic fibrosis (CF) patients. A prospective study by Lebecque et al. found that 5.8% of CF patients had at least one sputum culture positive for this common respiratory tract-colonizing fungus. This fungus is considered a potential marker for atypical CF and cause rapidly progressing invasive dermatitis [7]. It has been proven to be the best method for the rapid identification of pathogenic yeast from cultures [6], the databases used in routine clinical practice may not include *Exophiala spp.* [7]. Currently, molecular methods are increasingly replacing morphological methods for the identification of fungi. Species-specific PCR was introduced by Nagano et al. in 2008 and was the first successful sequencing method, which is based on sequencing of the ribosomal DNA (rDNA) operon and its region [10]. Most researchers believe that sequencing based on rDNA transcription spacers can obtain accurate species identification [7, 11]. A revision and update of the consensus definitions of invasive fungal disease by the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSG) (2019) added tissue nucleic acid diagnosis as a criterion for proven invasive fungal disease [12]. However, tissue nucleic acid diagnosis data is based mostly on *Aspergillus* infection, and its value in the diagnosis of other rare pulmonary fungal diseases needs additional research. In our case, multiple pathologies suggested inflammation, one of which suggested TB infection, but combined with the clinical characteristics, we were skeptical of TB infection and finally diagnosed the patient with *Exophiala dermatitidis* infection using tissue nucleic acid testing combined with treatment response data.

Regarding treatment, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)/European Confederation of Medical Mycology (ECMM) guidelines recommend the use of azoles, such as voriconazole and posaconazole. Several antifungal susceptibility test results for *Exophiala dermatitidis* have been reported. Nweze et al. analyzed 16 isolates and found that almost all strains were sensitive to amphotericin B, 5-fluorocytosine, itraconazole, fluconazole and voriconazole [13]. Another study showed that amphotericin B was active against all tested species except *Exophiala mesophila*, with minimum inhibitory concentration (MIC) values of 1 μg/mL [11]. Gao et al. reported that voriconazole, itraconazole and posaconazole were active against *Exophiala dermatitidis* [14]. Triazole combined with flucytosine, amphotericin B combined with flucytosine, amphotericin B combined with terbinafine, and posaconazole combined with amphotericin B all showed synergistic activity [15–18]. In contrast, echinocandins have weak antifungal activity. It is worth noting that a breakthrough infection during prevention and treatment with micafungin has also been reported [19].

After re-examining our case, we diagnosed *Exophiala dermatitidis* infection based on the mNGS results and continued the oral administration of voriconazole. After 2.5 months, most of the lesions had been significantly
absorbed, but the dorsal lesion had progressed, and indications of drug-induced liver damage were observed. Considering a possible decrease in drug sensitivity, we adjusted the treatment to amphotericin B combined with posaconazole. Because of the cost involved, amphotericin B was finally administered. After 3 months, the lesion had been significantly absorbed. We adjusted the treatment to posaconazole for half a month in the later period. There was no evidence of recurrence at follow-up after treatment withdrawal. Although there is currently no established targeted PCR method for the detection of Exophiala dermatitidis from formalin-fixed paraffin-embedded (FFPE) tissue DNA, we believe a definitive diagnosis of pulmonary Exophiala dermatitidis infection can be established based on the current guidelines and during the treatment process.

Due to the limited culture technology available for the detection of this rare fungus, we failed to obtain drug sensitivity results; previous studies found that susceptibility test results for clinical isolates of Exophiala dermatitidis showed some differences. Therefore, if our patient had experienced a poor therapeutic effect, it would have been very difficult to select an appropriate antifungal drug therapy. Additionally, we discussed the positive antacid fluorescence and antacid 2 test results with the pathologist. Subsequently, the pathologist examined the pathological sections and performed staining of the same tissue again, which revealed negative antacid fluorescence results, and no acid-fast bacteria were observed. Considering the treatment course and the mNGS results, we are sure that the original results were false positives and considered the samples to have been contaminated. Due to the high incidence of TB in China and the fact that the respiratory pathology center of our hospital receives and processes a large number of clinical specimens from patients with complex infections that show a high acid-fast bacilli positivity rate, we speculate that the most likely source of the contamination was from the water bath for the paraffin sections.

Finally, some insights from our case are as follows: (1) the importance of symptoms at follow-up, follow-up chest CT, and efficacy and safety assessments, should be emphasized; and (2) the importance of molecular techniques, such as mNGS, for the identification of rare fungi should be emphasized. This will improve the pathogen diagnosis rate when combined with other clinical microbiological tests.

Abbreviations
mNGS: Metagenomic next-generation sequencing; LRTI: Lower respiratory tract infection; TB: Tuberculosis; IGRA: Interferon gamma release assay; BALF: Bronchoalveolar lavage fluid; GM: Galactomannan; BG: (1 → 3)-β-D-glucan; ALT: Alanine aminotransferase; CF: Cystic fibrosis; MALDI-TOF: Matrix-assisted laser desorption ionization time-of-flight; EORTC/MSGERC: European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium; ESCMID: European Society of Clinical Microbiology and Infectious Diseases; ECMM: European Confederation of Medical Mycology.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12879-022-07399-y.

Additional file 1: Figure S1. Heatmaps of ANIb scores were constructed for 118 unique sequences of Exophiala dermatitidis from the patient and 12 Exophiala genomic sequences downloaded from the NCBI. Cells in the heatmap corresponding to a 95% or higher score (and therefore the same species) are colored in red. Orange cells correspond to ANIb scores of 95% or less, indicating that the corresponding organisms do not belong to the same species. Hierarchical clustering of the data in two dimensions is represented by dendograms constructed by simple linkage of the ANIb score.

Acknowledgements
We would like to thank the patient, along with the nurses and clinical staff who provided patient care, the staff of the hospital respiratory medicine department, the staff of the hospital clinical laboratories, and the technical staff of the State Key Laboratory of Respiratory Disease for their excellent assistance. We give special thanks to Yingying Gu, the director of pathology. Furthermore, we would also like to thank the AJE team for the English language editing of this manuscript.

Author contributions
ZTL and FY conceived and designed the study. ZTL, JLT, JPZ and MZX had full access to all data, take responsibility for the integrity of the data and the accuracy of the data analysis, and performed pathogen detection. WQZ and TX performed pathogen detection. JLT, SQL and JPZ contributed to the collection of data from the electronic medical record, SQH and YQZ contributed to the management and treatment of the patient and collection and processing of samples. All authors contributed to data acquisition, data analysis, or data interpretation and reviewed the final version of the manuscript. All authors read and approved the final manuscript.

Funding
This research was funded by the Guangzhou Municipal Science and Technology Bureau and ZHONGNANSHAN MEDICAL FOUNDATION OF GUANGDONG PROVINCE (ZNSA-2020003); the grant of State Key Laboratory of Respiratory Disease (SKLD-Z-202019); the Open Project of State Key Laboratory of Respiratory Disease (SKRD-OP-202102); and the Guangzhou Institute of Respiratory Health Open Project (2019GIRHZ06). The funders had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Availability of data and materials
The data that support the findings of the current study are available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
Ethical approval for this study was granted by the ethics committee of the First Affiliated Hospital of Guangzhou Medical University (No. 2019-49).

Consent for publication
Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the editor of this journal.

Competing interests
The authors report no conflicts of interest.
References

1. Chiu CY, Miller SA. Clinical metagenomics. Nat Rev Genet. 2019;20(6):341–55.
2. Simmer PJ, Miller S, Carroll KC. Understanding the promises and hurdles of metagenomic next-generation sequencing as a diagnostic tool for infectious diseases. Clin Infect Dis. 2018;66(5):778–88.
3. Chen H, Yin Y, Gao H, Guo Y, Dong Z, Wang X, Zhang Y, Yang S, Peng Q, Liu Y, et al. Clinical utility of in-house metagenomic next-generation sequencing for the diagnosis of lower respiratory tract infections and analysis of the host immune response. Clin Infect Dis. 2020;71(Suppl 4):S416–S426.
4. Byrd AL, Belkaid Y, Segre JA. The human skin microbiome. Nat Rev Microbiol. 2018;16(3):143–55.
5. Man WH, de SteenhuijsenPiters WA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017;15(5):259–70.
6. Kirchhoff L, Olsowski M, Rath PM, Steinmann J. Exophiala dermatitidis: key issues of an opportunistic fungal pathogen. Virulence. 2019;10(1):984–98.
7. Klasinc R, Riesenhuber M, Bacher A, Willinger B. Invasive fungal infection caused by Exophiala dermatitidis in a patient after lung transplantation: case report and literature review. Mycopathologia. 2019;184(1):107–13.
8. Grenouillet F, Cinor M, Pana-Karatali H, Person C, Gainer-Brun M, Malinge MC, Le Goeic Y, Richard-Thiriez B, Bouchara JP. Exophiala dermatitidis revealing cystic fibrosis in adult patients with chronic pulmonary disease. Mycopathologia. 2018;183(1):71–9.
9. Kantarcioğlu AS, de Hoog GS. Infections of the central nervous system by melanized fungi: a review of cases presented between 1999 and 2004. Mycoses. 2004;47(1–2):1–13.
10. Nagano Y, Elborn JS, Millar BC, Goldsmith CE, Rendall J, Moore JE. Development of a novel PCR assay for the identification of the black yeast, Exophiala (Wangella) dermatitidis from adult patients with cystic fibrosis (CF). J Cyst Fibros. 2008;7(6):576–80.
11. Silva WC, Gonçalves SS, Santos DW, Padovan AC, Bizerra FC, Melo AS. Species diversity, antifungal susceptibility and phenotypic and genotypic characterisation of Exophiala spp. infecting patients in different medical centres in Brazil. Mycoses. 2017;60(5):328–37.
12. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Verweij PE, Clancy CJ, Wingard JR, Lockhart SR, Groll AH, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367–76.
13. Nweze EI, Ezute S. Isolation and antifungal susceptibility of Exophiala dermatitidis isolates from human stool samples in Nigeria. Mycopathologia. 2010;169(3):201–6.
14. Gao L, Sun Y, He C, Zeng T, Li M. Synergistic effects of tacrolimus and azoles against Exophiala dermatitidis. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/AAC.00948-17.
15. Deng S, Lei W, de Hoog GS, Yang L, Vitale RG, Rafati H, Seyedmousavi M, Toloee A, van der Lee H, Liao W, et al. Combination of amphothericin B and terbinafine against melanized fungi associated with chromoblastomycosis. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/AAC.00270-18.
16. Chowdhary A, Meis JF, Guarro J, de Hoog GS, Kathuria S, Arendrup MC, Ankar-Akdagli S, Akova M, Boekhout T, Caira M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect. 2014;20(Suppl 3):47–75.
17. Schwarz C, Hartl D, Eickmeier O, Hector A, Benden C, Durieu I, Sole A, Gartner S, Milia CE, Barry PJ. Progress in definition, prevention and treatment of fungal infections in cystic fibrosis. Mycopathologia. 2018;183(1):21–32.
18. Deng S, Pan W, Liao W, de Hoog GS, Gerrits van den Ende AH, Vitale RG, Rafati H, Ilkit M, Van der Lee AH, Rijs AJ, et al. Combination of amphothericin B and flucytosine against neurotropic species of melanized fungi causing primary cerebral phaeohyphomycosis. Antimicrob Agents Chemother. 2016;60(4):2346–51.
19. Badali H, de Hoog GS, Sudhadham M, Meis JF. Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist. Med Mycol. 2011;49(8):819–24.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.